Introduction
============

The tear film contains a mixture of lipid, aqueous, and mucin layers. It is generally accepted that the tear film in subjects with ocular dryness is unstable and incapable of maintaining the protective qualities that are necessary for its structure and function.

When the tear film is compromised, the corneal and conjunctival epithelium cannot be maintained, and subjects experience the symptoms of discomfort associated with ocular dryness such as burning, stinging, grittiness, foreign body sensation, tearing, ocular fatigue, and dryness ([@b12-co-2-629]). The mainstay therapy of ocular dryness is tear film correction and improvement with topically administered lubricant eye drops substitutes, which provide mostly a transient relief due to low retention time on the eye surface.

Systane^®^ Lubricating Eye Drops (Alcon Laboratories, Inc., Fort Worth, Texas, USA) contain polyethylene glycol 400 (0.4%) and propylene glycol (0.3%) demulcents with the polymer hydroxypropyl guar (HP-Guar) as a gelling agent, and are preserved with POLYQUAD^®^ (polidronium chloride) 0.001%. In the bottle, Systane^®^ consists of a loosely cross-linked meshwork created by covalent interactions between borate and HP-Guar. When exposed to the higher pH of the ocular surface and tears, which is approximately 7.5 ([@b14-co-2-629]), HP-Guar forms a reversible cross-link with borate, resulting in a gel-matrix with sheer thinning viscoelastic and bioadhesive properties ([Figure 1](#f1-co-2-629){ref-type="fig"}). The gel-matrix is designed to promote retention of the active demulcents, and, thus, protects the ocular surface ([@b1-co-2-629]; [@b7-co-2-629]; [@b5-co-2-629]; [@b10-co-2-629]).

The purpose of this study was to examine the clinical efficacy of Systane^®^ Lubricating Eye Drops in reducing the subjective symptoms of moderate ocular dryness in a specific patient population.

Methods
=======

Study population
----------------

Fifty healthy adults, regardless of gender or race, were enrolled at one research site in Bologna, Italy. The study was approved by an Independent Ethics Committee and was conducted in accordance with the current ethical principals of the Declaration of Helsinki and in accordance with the current legislation on clinical research in Italy. All subjects signed an informed consent form before starting the study. The inclusion/exclusion criteria were designed to exclude subjects with mild symptoms of ocular dryness, and to include subjects with moderate symptoms of ocular dryness ([Table 1](#t1-co-2-629){ref-type="table"}).

Materials
---------

Sterile saline (0.9% NaCl, Mini-Plasco. B. Braun, Meisungen, Germany) for the washout period. Systane^®^ Lubricating Eye Drops as the test article.

Study design
------------

This was a prospective, open-label, single-center study. The study consisted of 3 office visits carried out in an approximately 5-week period -- visit 1 (screening), visit 2 (Day 0/baseline, 3--5 days after visit 1), and visit 3 (Day 28/endpoint, 28 days after visit 2). Each visit was conducted at approximately the same time of day (in the afternoon). Subjects' tear film break-up time (TFBUT) had to be \<10 seconds, and subjects had to have at least 1 ocular discomfort symptom in addition to dryness to be eligible. Saline was used for a run-in period of 3--5 days. At the screening visit, subjects' demographic information was recorded, along with current/prior use of medications, lubricant eye drops, and ocular pathologies ([Table 2](#t2-co-2-629){ref-type="table"}). Medications considered necessary to maintaining subjects' health were used at the discretion of the investigator. Subjects were questioned on how often their eyes felt dry enough for them to want to use lubricant eye drops (none, some, half, most, or all of the time). Furthermore, subjects were asked to complete an "Ocular Discomfort -- Severity Questionnaire" grading the severity of their ocular sensations (burning, stinging, grittiness, dryness, foreign body sensation, and itching) on a 4-point scale (Grade: 0 = no discomfort; 1 = mild discomfort; 2 = moderate discomfort; 3 = serious discomfort).

A thorough slit-lamp biomicroscope examination was conducted to examine and record any abnormalities in the lids/eyelashes, anterior chamber, iris, and lens, as well as to grade the level of conjunctival injections (Grade: 0 = none -- normal, no hyperemia; 1 = mild, trace hyperemia; 2 = moderate, diffuse hyperemia; 3 = severe, horizontal banding of hyperemia). TFBUT, which is defined as the time taken from blink until the first dark spots or streaks appear within the fluorescein enhanced tear film ([@b2-co-2-629]), was measured and recorded (average of 3 measurements) using sodium fluorescein strips (Haag-Streit International). Subjects who met the inclusion criteria of the study were dispensed saline solution as a run-in drop. This served to normalize the study population to an identical regimen of eye drops use, and allowed for washout and minimization of any effect from previous lubricant eye drops/medications use. Subjects were instructed to use the saline drops 4 times daily (qid) in both eyes. In addition, subjects were instructed to administer the saline eye drops at 8:00 AM on the day of their next office visit (Day 0/baseline) and to refrain from administering any other eye drops until after the examination. This allowed for approximately 6 hours between the last administration of eye drops and TFBUT measurements.

After 3--5 days, subjects returned (visit 2: Day 0/baseline) for an eligibility follow-up examination in which the above measurements were repeated. In addition, subjects answered a satisfaction questionnaire. Subjects continuing to satisfy the inclusion criteria were dispensed Systane^®^ Lubricating Eye Drops and were instructed to use 1--2 drops in each eye qid (upon awakening, noon, early evening, and before bedtime). Likewise, subjects were instructed to administer Systane^®^ drops at 8:00 AM on the day of their next office visit (Day 28/endpoint) and to refrain from administering any other eye drops until after the examination. After 28 days (visit 3: Day 28/endpoint), subjects returned for follow-up. The same examination measures and questions of visits 1 and 2 were repeated. In addition, subjects were asked to complete a satisfaction questionnaire. The satisfaction questionnaire included the following statements: "my eyes feel dry in the morning," "my eyes feel dry at the end of the day," "my eyes feel comfortable upon instillation of drops," "my eyes feel refreshed when I use the drops," "my eyes feel refreshed longer than expected when I use the drops," and "I frequently forget my symptoms during the use of the drops." Subjects recorded their answers using a 5-point scale (Scale: 1 = strongly disagree, 2 = disagree, 3 = undecided, 4 = agree, and 5 = strongly agree). Adverse events were also reported on visit 3.

Statistical analysis
--------------------

The usual descriptive statistics were performed for all variables: average, standard deviation (SD), mean, minimum/maximum value for continuous variables, and absolute/relative frequency of categorical variables. Also, a *t* test was used with a bilateral significance level of 5%.

Results
=======

Fifty subjects were enrolled and successfully completed all aspects of the study. The mean age of subjects was 57.6 ± 15.4 years (range, 26--85); 40 subjects were female. When asked how often their eyes felt dry enough to want to use lubricant eye drops, none of the subjects responded with "none of the time," 30 subjects responded "some," 17 "half," 2 "most," and 1 subject responded "all of the time." When questioned regarding their current use of lubricating eye drops, 44 subjects reported use of lubricating eye drops.

Tear film break-up time
-----------------------

The tear film analysis showed no significant changes in TFBUT between screening and baseline visit (6.8 seconds OD and 6.9 seconds OS). However, a statistically significant increase was observed in the mean sodium fluorescein TFBUT from 6.9 seconds at baseline visit to 8.5 seconds at the endpoint visit (Day 28) in the left eye, and from 6.8 seconds to 8.5 seconds in the right eye (p = 0.0001) ([Figure 2](#f2-co-2-629){ref-type="fig"}).

Ocular discomfort symptoms
--------------------------

No significant changes in ocular discomfort symptoms were observed between screening and baseline visits. A significant improvement was recorded over the 28-day period of the trial for all reported sensations from the Ocular Discomfort -- Severity questionnaire ([Figure 3](#f3-co-2-629){ref-type="fig"}). Burning sensation was reported as "moderate" by 13/50 and "serious" by 1/50 subjects at baseline visit. At the endpoint visit, burning sensation was reported as "moderate" by 4/50 and "serious" by 0/50 subjects. Stinging sensation was reported as "moderate" by 7/50 subjects at baseline visit and by 3/50 subjects at the endpoint visit. These data attest to the ability of Systane^®^ to improve the subjective ocular discomfort symptoms of ocular dryness.

Overall subjects' satisfaction
------------------------------

A significant difference was observed with the overall satisfaction questions at endpoint visit. Compared with baseline visit, most subjects agreed with the statements "My eyes feel refreshed when I use the drops" (44/50), "My eyes feel comfortable upon instillation of the drops" (36/50), and "My eyes feel refreshed longer than expected when I use the drops" (21/50). Most subjects responded with "undecided" to the statements "My eyes feel dry at the end of the day" (27/50), "I frequently forget my symptoms during the use of the drops" (27/50), and "My eyes feel dry in the morning" (21/50) ([Figure 4](#f4-co-2-629){ref-type="fig"}).

Discussion
==========

Ocular dryness arises from inadequate lubrication of the ocular surface from a variety of underlying conditions and environmental factors. Though there are many contributing factors, ocular dryness is due predominantly to either aqueous deficiency or excessive evaporation of the tear film. Although new therapeutic strategies based on the pathophysiology of ocular dryness are currently being developed, lubricating eye drops continue to be the mainstay care of ocular dryness. The major goal of these products is to restore ocular surface integrity in an attempt to reduce the symptoms associated with ocular dryness. Systane^®^ Lubricating Eye Drops provide a physical protective barrier that works in conjunction with blinking to help spread the tear film over the eye surface. A protected ocular surface, in fact, will exist as long as the tear film is stable and when the TFBUT matches or exceeds the inter-blink interval (IBI). Conversely, when the TFBUT is less than the IBI, the corneal surface will be unprotected for a period of time between blinks, leading to ocular dryness ([@b11-co-2-629]).

Systane^®^ works by binding to the hydrophobic exposed areas of the epithelial cells, attaching a protective HP-Guar tear-gel matrix that helps restore the ocular surface and increase TFBUT ([@b9-co-2-629], [@b8-co-2-629]). [@b13-co-2-629] demonstrated that Systane^®^ provided long-term protection from desiccation of the intact cornea. In Ubels' study, Systane^®^ allowed the in vivo exposed corneal epithelium to recover the normal barrier function.

The purpose of this current study was to obtain further evidence of the clinical efficacy of Systane^®^ in reducing ocular discomfort symptoms of ocular dryness by increasing TFBUT. This study has demonstrated that the use of Systane^®^ qid over a 28-day period statistically significantly extended TFBUT. Other studies have investigated the ocular surface retention properties of Systane^®^ and its effects on corneal and conjunctival staining as well as TFBUT. Gifford et al conducted a similar study and showed significant improvement in ocular symptoms and TFBUT ([@b5-co-2-629]). The authors reported that the gelling properties of HP-Guar might be responsible for the stability of the ocular surface through its retention of the demulcents on the ocular surface. Systane^®^ significantly increased TFBUT up to 30 minutes post instillation compared with carboxymethylcellulose 0.5% and polysorbate 80/glycerin (Refresh Tears^®^ and Refresh Endura^™^, Allergan, Inc., Irvine CA, USA), presumably due to the HP-Guar borate gel-matrix component ([@b11-co-2-629]). Guillon et al demonstrated that Systane^®^ significantly increased TFBUT at each measurement (30 minutes interval) up to 120 minutes post instillation ([@b6-co-2-629]). The ocular protection index (OPI) is a measure of the ratio of TFBUT to the IBI. D'Arienzo et al demonstrated that Systane^®^ exhibited a greater extension in TFBUT from baseline at 45, 60, and 90 minutes postdrop instillation than Optive^™^ during the important sustaining phase, indicating its ability to lubricate and protect the ocular surface for a longer period than Optive. However, both Systane^®^ and Optive^™^ showed improvements shortly after instillation during the bulking phase ([@b4-co-2-629]).

The overall results from the Ocular Discomfort -- Severity questionnaire showed that the use of Systane^®^ during the course of this study was associated with a significant reduction of ocular discomfort. Two similar studies conducted by [@b5-co-2-629] and [@b7-co-2-629] asking the same questions over the same duration and using an identical Systane^®^ regimen also showed significant overall reduction of ocular discomfort. Therefore, this current study adds more evidence and weight to the conclusions drawn by Gifford and Hartstein, which state that Systane^®^ is effective in improving ocular discomfort in subjects with moderate symptoms of ocular dryness, one of the primary roles of lubricating eye drops.

The final part of this study examined the subjects' overall satisfaction with Systane^®^ as lubricant eye drops by looking into subjects' responses to 6 acceptability elements at the endpoint visit. [@b5-co-2-629], [@b7-co-2-629], and [@b3-co-2-629] reported the use of similar questions and the receipt of similar responses in their corresponding clinical studies. Subjects were aware of the relief Systane^®^ provided, agreeing more strongly to "My eyes feel refreshed when I use the drops." The frequency of symptoms was also reduced, with most subjects agreeing, "My eyes feel refreshed longer than I expected." Some subjects could not answer some of the acceptability questions and reported "uncertain/undecided" as their answer. One possible reason may be the ambiguity of the statements themselves, leaving the patient undecided.

Limitations of this study are that it was an open-label and uncontrolled study that did not control for the placebo effects or compare the results with that of a control group, although the symptoms at the endpoint visit were compared with the symptoms at the baseline visit. Therefore, a future double-masked, randomized, controlled study design with perhaps longer duration to study the long-term effects of Systane^®^ on ocular dryness is warranted.

Conclusion
==========

Systane^®^ Lubricating Eye Drops improved the symptoms of ocular discomfort in subjects with moderate symptoms of ocular dryness. Statistically significant improvement was evident in the extension of TFBUT from Day 0/baseline to Day 28/endpoint. Subjective symptoms also showed significant improvement and overall, subjects were satisfied with the use of Systane^®^.
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###### 

Inclusion and exclusion criteria

  Condition            Criteria
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria   Subjects who answer "some of the time", "half of the time", "most of the time", or "all of the time" to the question "how often have your eyes felt dry enough to want to use eye drops?"Subjects who, in addition to complaining of ocular dryness sensation, exhibit at least one of the following symptoms of ocular discomfort: burning, stinging, grittiness, foreign body sensation, or ocular irritationSubjects with a tear film break-up time (TFBUT) \<10 secondsSubjects who will possibly comply with the study procedures
  Exclusion criteria   Subjects who answer "none of the time" to the question "how often have your eyes felt dry enough to want to use eye drops?"Subjects with a tear film break-up time (TFBUT) ≥10 secondsSubjects who have had refractive eye surgery in the last 6 monthsSubjects that use concurrent ocular treatment, not including lubricant eye drops or lubricantsSubjects known to be allergic to any of the components of SystaneSimultaneous participation in other medical studies

###### 

Percentage of subjects' current/prior medications, lubricating eye drops, and ocular pathologies at screening visit

                             Medication or ocular pathology                               Number of subjects (%)
  -------------------------- ------------------------------------------------------------ ------------------------
  Ocular treatments          Hyaluronic acid                                              16 (32)
                             Eye drops/Hyalistil                                          7 (14)
                             Gental                                                       4 (8)
                             Benzalkonium chloride/Celluvisc                              3 (6)
                             Carbomer/Cellufresh/Hyaluronate/Siccafluid/sodium chloride   2 (4)
                             Hylocomod/Lacrinorm/Retinol/Systane/Tetramil                 1 (2)
  Ongoing ocular pathology   Cataract                                                     2 (4)
                             Pinguecola                                                   1 (2)
                             Pseudophakia                                                 1 (2)
                             Strabismus                                                   1 (2)
  Prior ocular pathology     Cataract surgery                                             1 (2)
                             Pseudophakia                                                 1 (2)
                             Retinal detachment                                           1 (2)
